



### Corporate Profile

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances. Our lead TLR9 agonist, IMO-2125, is currently in a Phase 1 trial for the treatment of hepatitis C virus infection. We have also created novel DNA-based compounds that have been shown to act as antagonists to TLR7 and TLR9 in preclinical studies, and we selected IMO-3100 as the lead antagonist candidate for preclinical development for autoimmune diseases.

### Primary IR Contact

Investor Relations  
**Phone:** 617.679.5500  
**E-mail:** ir@iderapharma.com

For application of our TLR-targeted compounds for asthma and allergy, as adjuvants for vaccines, and for oncology, we have entered into three collaborative alliances. We are collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications. We are also collaborating with Merck & Co., Inc. for the use of Idera's TLR7, 8 and 9 agonists in combination with Merck & Co.'s therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer's disease. In addition, we are collaborating with Merck KGaA for the research, development and commercialization of Idera's most advanced clinical candidate, IMO-2055, as well as IMO-2125 and other TLR9 agonists for the treatment of cancer. Merck & Co. of the U.S. is not related to Merck KGaA of Germany.

Idera is a publicly traded company that trades on the Nasdaq Global Market under the symbol "IDRA". Detailed financial information about the Company is available by referring to the most recent quarterly filing on Form 10-Q or Annual Report on Form 10-K as filed with the Securities & Exchange Commission.

### Stock Performance

#### IDRA (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$3.35
Change (%)	▼ 0.09 (2.62%)
Volume	14,647
52 Week Low	\$3.02
Market Cap	\$92,326,000
Rolling EPS	-0.14
PE Ratio	0
Shares Outstanding	27,560,000

Data as of 09/08/10 3:59 p.m. ET

■ IDERA PHARMACEUTICALS INC  
as of 9/7/2010



EDGAROnline

## Recent Headlines

09/08/10  
Idera Pharmaceuticals to Present at Upcoming Investor Conferences

08/27/10  
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment


08/05/10  
Idera Pharmaceuticals Reports Second Quarter 2010 Financial Results and Provides Pipeline Update

## Events

Date	Title
09/15/10 10:50 a.m. ET	<b>Idera Pharmaceuticals, Inc. at Rodman &amp; Renshaw Global Investment Conference</b> <b>Location</b> New York, NY
09/20/10 7:30 a.m. ET	<b>Idera Pharmaceuticals, Inc. at UBS Global Life Sciences Conference</b> <b>Location</b> New York, NY

## Analyst Estimates / Ratings

Mean Recommendation: 1.7



## EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 10	-0.10	-0.05	-0.05
QTR	Dec 10	-0.16	0.04	0.04
QTR	Mar 11	-0.19		
QTR	Jun 11	-0.20		
FY	Dec 10	-0.35	-0.06	-0.06
FY	Dec 11	-0.61	-0.11	-0.11

## SEC Filings

Filing Date	Form
09/03/10	EFFECT
08/26/10	S-3
08/12/10	3
08/12/10	SC 13G

## Corporate Governance

Sudhir Agrawal, D. Phil.	President, Chief Executive Officer and Chief Scientific Officer
Louis J. Arcudi III, MBA	Chief Financial Officer, Treasurer, and Secretary
Robert David Arbeit, M.D.	Vice President, Clinical Development
Timothy M. Sullivan, Ph.D.	Vice President, Development Programs and Alliance Management
Rahul Jasuja, Ph.D	Vice President, Corporate Development
Ekambar R. Kandimalla, Ph.D.	Vice President, Discovery
Nicola La Monica, Ph.D.	Vice President, Biology
Steven J. Ritter, Ph.D., J.D.	Vice President, Intellectual Property and Contracts

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	55	33.43	31.2	8,590,195
Mutual Fund	74	8.03	5.7	1,565,130
Insider *	29	85.51	91.8	25,299,144

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Senator Investment Group LP	3,234,505	11.7	3,234,505	08/04/10
Merck & Co.	1,818,182	6.6	0	01/31/10
Promark Investment Advisors, Inc.	573,638	2.1	0	06/30/10
El-Zein (Youssef)	511,978	1.9	-43,358	01/31/10
Dimensional Fund Advisors, LP	360,687	1.3	3,823	06/30/10
Baker Brothers Advisors, L.L.C.	288,401	1.1	26,231	06/30/10
AWM Investment Company, Inc.	280,700	1.0	280,700	06/30/10
Vanguard Group, Inc.	274,350	1.0	-18,965	06/30/10
Agrawal (Sudhir)	126,277	0.5	-6,615	01/31/10
Susquehanna Financial Group, LLLP	121,434	0.4	121,434	06/30/10

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed